Study guide
5.2 Substance Use Disorders & Co-Occurring Conditions
Board-Certified Case Manager CCM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Care Management Foundations & Assessment
1.1 The Case Management Process & Core Frameworks 1.2 Comprehensive Patient Assessment & Acuity Stratification 1.3 Individualized Care Planning & Goal Setting 1.4 Medication Safety, Cost Containment & Care-Setting Selection
2 Chapter 2: Care Coordination & Transitions of Care
2.1 Interdisciplinary Care Coordination & Team Collaboration 2.2 Care Transitions & Safe Discharge Planning 2.3 Cross-Setting Communication & Readmission Prevention
3 Chapter 3: Healthcare Reimbursement Systems & Payer Models
3.1 Medicare Coverage, Rules & Statutory Requirements 3.2 Medicaid Programs, Eligibility & State-Federal Regulations 3.3 Commercial Insurance, Managed Care & Utilization Management 3.4 Military, Veterans' & Government Benefit Programs
4 Chapter 4: Value-Based Care & Coding Methodologies
4.1 Value-Based Reimbursement, ACOs & Bundled Payments 4.2 Healthcare Coding Systems (ICD-10, CPT, DRGs) 4.3 Revenue Cycle Management & Financial Advocacy
5 Chapter 5: Psychosocial Assessment & Behavioral Health
5.1 Behavioral Health Screening & Mental Health Disorders 5.2 Substance Use Disorders & Co-Occurring Conditions 5.3 Crisis Intervention & Suicide Risk Management 5.4 Trauma-Informed Care, Abuse & Neglect Screening
6 Chapter 6: Social Determinants, Culture & Support Systems
6.1 Social Determinants of Health (SDOH) & Community Resources 6.2 Cultural Competency, Health Literacy & Communication 6.3 Family Dynamics, Caregiver Support & Support Systems 6.4 Counseling Theories, Stages of Change & Motivational Interviewing 6.5 Supportive Care, Gender Health & Wellness Promotion
7 Chapter 7: Quality Improvement, Safety & Outcomes
7.1 Healthcare Quality Metrics & Performance Improvement (PDSA/RCA) 7.2 Patient Safety, Risk Management & Sentinel Events 7.3 Outcome Measurement, Benchmarking & Accreditation Standards 7.4 Healthcare Data Analytics, Cost-Benefit Analysis & Value-Based Care Impact
8 Chapter 8: Post-Acute Care & Rehabilitation Concepts
8.1 Continuum of Post-Acute Care Settings (SNF, LTACH, IRF) 8.2 Rehabilitation Strategies & Functional Assessments 8.3 Disability Management, Return-to-Work & Assistive Technology
9 Chapter 9: Ethical, Legal & Professional Practice Standards
9.1 The Commission Code of Professional Conduct & Ethical Decision-Making 9.2 Healthcare Law, HIPAA, Confidentiality & Informed Consent 9.3 Patient Advocacy, Scope of Practice & Legal Guardianship 9.4 Documentation Standards, Case Summaries & Regulatory Compliance
5.2 Substance Use Disorders & Co-Occurring Conditions
Key Takeaways Explain This Topic AI
Substance Use Disorder (SUD) is a chronic, relapsing brain disease requiring evidence-based screening, harm reduction, and non-stigmatizing case management.
The SBIRT framework (Screening, Brief Intervention, and Referral to Treatment) enables early identification and motivation for change across healthcare settings.
Medication-Assisted Treatment (MAT/MOUD)—including buprenorphine, methadone, and naltrexone for OUD, and naltrexone, acamprosate, and disulfiram for AUD—substantially improves retention and reduces mortality.
Initiating buprenorphine too soon after full agonist opioid use precipitates severe withdrawal; naltrexone requires a strict 7–14 day opioid-free washout period.
Integrated Dual Disorder Treatment (IDDT) provides concurrent, unified treatment for co-occurring psychiatric and substance use disorders by a single clinical team, outperforming historical sequential or parallel care models.
Last updated: July 2026
5.2 Substance Use Disorders & Co-Occurring Conditions
Quick Answer: Certified Case Managers must approach Substance Use Disorders (SUD) as chronic, treatable brain conditions. Effective management requires universal screening via tools like AUDIT , CAGE , and DAST-10 , structured application of the SBIRT framework, adoption of harm reduction principles, coordination of Medication-Assisted Treatment (MAT/MOUD) , and implementation of Integrated Dual Disorder Treatment (IDDT) for co-occurring mental health and addiction disorders.
Overview of Substance Use Disorders (SUD)
DSM-5 defines Substance Use Disorder as a cluster of cognitive, behavioral, and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems. Criteria span four domains: impaired control, social impairment, risky use, and pharmacological criteria (tolerance and withdrawal).
Severity Grading (based on 11 DSM-5 criteria):
- Mild: 2–3 criteria met
- Moderate: 4–5 criteria met
- Severe: 6 or more criteria met
- Primary Substance Use Disorders
- Alcohol Use Disorder (AUD)
Clinical Complications: Chronic heavy alcohol use leads to hepatic cirrhosis, pancreatitis, cardiomyopathy, peripheral neuropathy, and cognitive deficits (Wernicke-Korsakoff syndrome due to thiamine/Vitamin B1 deficiency).
Withdrawal Assessment: Alcohol withdrawal can be life-threatening (delirium tremens, seizures). Evaluated clinically using the CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) scale.
Opioid Use Disorder (OUD)
Intoxication vs. Withdrawal:
Intoxication: Miosis (pinpoint pupils), respiratory depression, sedation, bradycardia, slurred speech. Overdose reversal requires immediate naloxone (Narcan) administration.
Withdrawal: Measured via the COWS (Clinical Opiate Withdrawal Scale) . Symptoms include lacrimation, rhinorrhea, piloerection ("goosebumps"), yawning, tachycardia, mydriasis (dilated pupils), abdominal cramps, diarrhea, and intense craving. Withdrawal is agonizing but rarely life-threatening in adults without severe medical comorbidities.
Stimulant Use Disorder (Cocaine, Methamphetamine, Prescription Amphetamines)
Presentation: Tachycardia, hypertension, hyperthermia, pupillary dilation, agitation, paranoia, and severe psychological craving.
Treatment Note: Unlike OUD and AUD, there are currently no FDA-approved pharmacotherapies (MAT) for stimulant use disorder. Evidence-based behavioral interventions—specifically Contingency Management (CM) and Cognitive Behavioral Therapy (CBT)—represent the gold standard.
- Screening Tools & The SBIRT Framework [ SCREENING ] ──────► Validated Tools (AUDIT, CAGE, DAST-10)
- │
- ▼
- [ BRIEF INTERVENTION ] ──► Motivational Interviewing (Explore Ambivalence)
- │
- ▼
- [ REFERRAL TO TREATMENT ] ─► Warm Handoff to Specialized Care (MAT / IDDT)
- Standardized Screening Tools
Tool Target Substance Format & Structure Clinical Cut-offs & Interpretation
AUDIT Alcohol 10-item WHO questionnaire assessing consumption, dependence, and consequences Score ≥ 8 \ge 8 ≥ 8 indicates hazardous/harmful drinking; score ≥ 20 \ge 20 ≥ 20 suggests alcohol dependence
AUDIT-C Alcohol 3-item brief screen focusing strictly on alcohol consumption patterns Score ≥ 4 \ge 4 ≥ 4 (men) or ≥ 3 \ge 3 ≥ 3 (women) is positive for hazardous drinking
CAGE Alcohol 4-item mnemonic screen ( C ut down, A nnoyed, G uilty, E ye-opener) Score of ≥ 2 \ge 2 ≥ 2 indicates positive screen for alcohol abuse/dependence
DAST-10 Illicit/Rx Drugs 10-item self-report tool assessing drug use (excluding alcohol and tobacco) Score 1–2 (low), 3–5 (moderate), 6–8 (substantial), 9–10 (severe risk)
The SBIRT Framework
SBIRT (Screening, Brief Intervention, and Referral to Treatment) is an evidence-based practice used to identify, reduce, and prevent problematic use, abuse, and dependence on alcohol and illicit drugs.
Screening (S): Universal screening in primary care, EDs, or inpatient units using standardized tools (AUDIT-C, DAST-10) to quickly assess risk level.
Brief Intervention (BI): A 5- to 15-minute motivational conversation for individuals screening at moderate risk. Uses Motivational Interviewing (MI) techniques to raise awareness of risks, explore ambivalence, and enhance internal motivation to change behavior.
Referral to Treatment (RT): Facilitation of a seamless "warm handoff" to specialized addiction treatment, MAT clinics, or intensive outpatient programs for individuals screening at high risk or showing severe SUD.
Harm Reduction Principles
Harm reduction is a pragmatic, compassionate public health approach focused on reducing the negative health, social, and economic consequences of substance use without mandating total abstinence as a prerequisite for receiving support.
Key Harm Reduction Interventions for Case Managers:
Naloxone (Narcan) Distribution & Training: Providing overdose reversal kits and educating patients, families, and community members on administration.
Syringe Services Programs (SSPs): Providing sterile needles and syringes to prevent blood-borne pathogen transmission (HIV, Hepatitis C).
Fentanyl Test Strips (FTS): Enabling drug checking to prevent accidental overdose from fentanyl-contaminated illicit substances.
Low-Barrier Housing / Housing First: Providing permanent supportive housing without requiring sobriety or treatment compliance prior to entry.
Stigma Elimination: Replacing non-compliant/judgmental terms ("clean/dirty drug screen") with objective clinical terminology ("negative/positive urine drug screen").
Medication-Assisted Treatment (MAT / MOUD)
MAT combines FDA-approved medications with behavioral therapies to treat substance use disorders.
Pharmacotherapy for Opioid Use Disorder (MOUD)
Medication Mechanism of Action Prescribing / Dispensing Rules Key Clinical & CM Considerations
Buprenorphine (Suboxone, Subutex) Partial Opioid Agonist (high affinity, partial intrinsic activity, ceiling effect on respiratory depression) Can be prescribed in office-based settings by authorized clinicians (MAT Act removed X-Waiver) Must initiate during mild-to-moderate withdrawal (COWS score ≥ 11 − 13 \ge 11-13 ≥ 11 − 13 ). Initiating too early causes precipitated withdrawal
Methadone Full Opioid Agonist (suppresses withdrawal and cravings, produces cross-tolerance) Strictly dispensed through federally regulated Opioid Treatment Programs (OTPs) requiring daily clinic visits initially Requires ECG monitoring for QTc prolongation. High risk of overdose if combined with sedatives/alcohol
Naltrexone (Vivitrol IM monthly, Oral daily) Full Opioid Antagonist (blocks opioid receptors; no abuse potential or physical dependence) Prescribed in any healthcare setting; monthly extended-release injection enhances adherence Requires complete opioid detoxification ( 7–14 days opioid-free ) prior to initiation. Administering too soon triggers severe precipitated withdrawal
Pharmacotherapy for Alcohol Use Disorder (AUD)
Naltrexone (Oral / Vivitrol IM): Blocks mu-opioid receptors, reducing alcohol cravings and the reinforcing "high" of drinking. Contraindicated in acute hepatitis or liver failure.
Acamprosate (Campral): Modulates glutamate and GABA neurotransmission, reducing protracted withdrawal distress and craving. Preferred in patients with liver disease because it is renally excreted ( contraindicated if CrCl < 30 < 30 < 30 mL/min ).
Disulfiram (Antabuse): Alcohol deterrent that inhibits aldehyde dehydrogenase. Consuming alcohol causes immediate, severe accumulation of acetaldehyde, resulting in flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension. Requires fully informed, highly motivated clients due to severe reaction risks.
Dual Diagnosis & Co-Occurring Conditions
Dual Diagnosis refers to the co-occurrence of at least one mental health disorder and at least one substance use disorder in the same individual. Approximately 50 % 50\% 50% of individuals with a severe mental illness experience a substance use disorder during their lifetime.
Models of Care for Dual Diagnosis
Sequential Model (Historical): Treat one disorder first (e.g., require 60 days of sobriety before treating PTSD). Outdated and ineffective; results in care denial.
Parallel Model (Historical): Patient attends two separate systems simultaneously (mental health clinic and addiction clinic). Leads to fragmented, conflicting care advice.
Integrated Dual Disorder Treatment (IDDT - Gold Standard): A single clinical team provides concurrent, coordinated treatment for both mental health and substance use disorders within the same program, using a unified, stage-wise treatment plan. [ IDDT Framework ] ──► Single Clinical Team ──► Unified Treatment Plan ──► Stage-Wise Interventions
Pillars of Integrated Care:
Stage-Wise Treatment: Interventions matched to the patient's stage of change (Engagement → \rightarrow → Persuasion → \rightarrow → Active Treatment → \rightarrow → Relapse Prevention).
Motivational Enhancement: Non-confrontational engagement addressing both psychiatric distress and substance use.
Assertive Outreach: Community-based case management bringing services directly to high-risk clients.
- Clinical Scenarios & Exam Traps
- Clinical Scenario: MAT Selection in AUD with Hepatic Impairment
A 52-year-old female with severe Alcohol Use Disorder and compensated alcoholic cirrhosis ( A S T / A L T > 3 × AST/ALT > 3\times A ST / A L T > 3 × upper limit of normal) expresses a strong desire to stop drinking. She requests medication to help control cravings.
Case Manager Action: Recognize that Naltrexone is hepatotoxic and contraindicated in acute hepatitis or liver failure. The case manager coordinates with the provider to initiate Acamprosate (Campral) , which is renally excreted and safe in hepatic impairment, while verifying baseline renal function.
Exam Trap 1: Demanding Sobriety as a Condition for Housing or Services Question trap: A case manager is arranging supportive housing for a homeless veteran with OUD. The housing provider demands 30 days of clean drug screens before placement. The exam option suggests agreeing to defer placement until sobriety is achieved. Incorrect! Evidence-based case management adheres to Housing First and harm reduction. sobrietymandates increase mortality and homelessness. The case manager advocates for low-barrier housing.
Exam Trap 2: Initiating Naltrexone Without an Opioid Washout Period Question trap: A patient with OUD took oral oxycodone 24 hours ago and wants to receive a Vivitrol (extended-release naltrexone) injection today. The option suggests administering the Vivitrol injection immediately. Incorrect! Administering a full antagonist like naltrexone within 7–14 days of opioid use causes sudden, excruciating precipitated withdrawal . A negative urine drug screen and opioid-free period are mandatory.
Exam Trap 3: Selecting Parallel or Sequential Treatment for Dual Diagnosis Question trap: A client with severe bipolar disorder and cocaine use disorder is refused mental health counseling until "they get clean from cocaine." The option suggests supporting the mental health center's policy. Incorrect! Modern standards mandate Integrated Dual Disorder Treatment (IDDT) . Denying psychiatric care due to active substance use violates best practices.